Susquehanna Fundamental Investments’s Xenon Pharmaceuticals XENE Stock Holding History

Susquehanna Fundamental Investments’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,400	Closed	-$301K	–	899
2023 Q1	$301K	Sell	8,400 -20,263	-71%	-$749K	0.01%	785
2022 Q4	$1.13M	Sell	28,663 -4,518	-14%	-$165K	0.02%	622
2022 Q3	$1.2M	Buy	+33,181	New	+$1.19M	0.02%	748
2022 Q1	$1.4M	Buy	45,647 +24,781	+119%	+$742K	0.03%	708
2021 Q4	$652K	Hold	20,866	–	–	0.02%	815
2021 Q3	$319K	Buy	+20,866	New	+$363K	0.01%	1384

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Susquehanna Fundamental Investments's XENE Position: Q2 2023 in Review

Susquehanna Fundamental Investments sold out of Xenon Pharmaceuticals (XENE) in Q2 2023, closing a stake of 8,400 shares — an estimated $301K sold.

Susquehanna Fundamental Investments first reported a position in XENE in Q3 2021 and held it in 6 quarters. The position peaked at $1.4M in Q1 2022. 175 funds tracked by Wall St. Rank hold XENE as of Q2 2023.

Susquehanna Fundamental Investments reported no remaining Xenon Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Susquehanna Fundamental Investments sold 8,400 Xenon Pharmaceuticals shares in Q2 2023, an estimated $301K.
Susquehanna Fundamental Investments first reported a position in Xenon Pharmaceuticals in Q3 2021 and held it in 6 quarters.
Susquehanna Fundamental Investments's Xenon Pharmaceuticals position peaked at $1.4M in Q1 2022.
175 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2023, filed 11 Aug 2023.